Teladoc (TDOC) Upgraded at ValuEngine

Teladoc (NYSE:TDOC) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report issued on Friday.

Several other research analysts also recently issued reports on TDOC. Canaccord Genuity upped their price objective on Teladoc from $42.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday. Jefferies Group assumed coverage on Teladoc in a report on Friday, January 26th. They set a “buy” rating and a $40.00 price objective on the stock. KeyCorp reaffirmed a “buy” rating and set a $39.00 price objective on shares of Teladoc in a report on Monday, December 4th. Citigroup assumed coverage on Teladoc in a report on Thursday, January 4th. They set a “buy” rating on the stock. Finally, CIBC reaffirmed an “outperform” rating and set a $45.00 price objective (up previously from $40.00) on shares of Teladoc in a report on Tuesday, November 21st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the stock. Teladoc currently has an average rating of “Buy” and a consensus price target of $39.43.

Teladoc (TDOC) traded down $1.75 during trading hours on Friday, reaching $35.30. The company’s stock had a trading volume of 1,346,196 shares, compared to its average volume of 1,284,640. Teladoc has a 12-month low of $19.60 and a 12-month high of $38.40. The company has a debt-to-equity ratio of 0.83, a quick ratio of 5.08 and a current ratio of 5.08.

In other Teladoc news, CFO Mark Hirschhorn sold 30,000 shares of the company’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $32.99, for a total transaction of $989,700.00. Following the completion of the sale, the chief financial officer now owns 5,203 shares in the company, valued at approximately $171,646.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jason N. Gorevic sold 100,000 shares of the company’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $32.99, for a total transaction of $3,299,000.00. Following the sale, the chief executive officer now owns 718,261 shares of the company’s stock, valued at approximately $23,695,430.39. The disclosure for this sale can be found here. Insiders own 4.47% of the company’s stock.

Several institutional investors have recently modified their holdings of the business. BlackRock Inc. raised its position in shares of Teladoc by 42.9% during the 2nd quarter. BlackRock Inc. now owns 3,844,402 shares of the health services provider’s stock valued at $133,400,000 after acquiring an additional 1,154,852 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Teladoc by 24.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,313,729 shares of the health services provider’s stock valued at $108,193,000 after acquiring an additional 650,129 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Teladoc by 11.5% during the 2nd quarter. Vanguard Group Inc. now owns 3,041,725 shares of the health services provider’s stock valued at $105,547,000 after acquiring an additional 314,646 shares during the last quarter. Eagle Asset Management Inc. increased its position in shares of Teladoc by 2.2% in the 3rd quarter. Eagle Asset Management Inc. now owns 2,106,830 shares of the health services provider’s stock valued at $72,053,000 after buying an additional 45,794 shares in the last quarter. Finally, Jennison Associates LLC increased its position in shares of Teladoc by 130.0% in the 3rd quarter. Jennison Associates LLC now owns 1,793,338 shares of the health services provider’s stock valued at $59,449,000 after buying an additional 1,013,707 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: “Teladoc (TDOC) Upgraded at ValuEngine” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.americanbankingnews.com/2018/02/04/teladoc-tdoc-upgraded-at-valuengine.html.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply